Common adverse events reported while on cabozantinib included fatigue (50%), anorexia (35%), AST elevation (35%), diarrhea (31%), hypertension (27%), abdominal discomfort, dyspepsia, ALT elevation (23% each), stomatitis, weight loss, rash, peripheral edema (15% each), and constipation (12%) (Table 2). Here, GPT is linked to hypertensive disorder.